Imeeng personal page - To The Moon

Imeeng

Imeeng

No personal profile

22Follow

5Followers

0Topic

0Badge

2021-09-10

Buy At dip?

Why Novavax Stock Slipped Thursday

2021-09-02

Market pls stay strong

Toplines Before US Market Open on Thursday

2022-07-19

$Novavax(NVAX)$🫠🫠🫠

2021-12-27

$Novavax(NVAX)$pls like

2021-08-23

$KE Holdings Inc.(BEKE)$Vomit blood

2022-08-15

$Novavax(NVAX)$Die Liao

2021-09-16

Like

BioNTech SE stock jumped 4% in morning trading

2021-09-23

$Alibaba(BABA)$won’t cut losses yet

2021-09-14

$Alibaba(BABA)$I’m planning to holdz

2021-08-21

$KE Holdings Inc.(BEKE)$Cut losses?

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3581901536452783","uuid":"3581901536452783","gmtCreate":1618807512375,"gmtModify":1629511756548,"name":"Imeeng","pinyin":"imeeng","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/e0aed7968b9134b940bf67762a13c6ea","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":5,"headSize":22,"tweetSize":0,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.05.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.61%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"80.37%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":9999447012,"gmtCreate":1660576694938,"gmtModify":1676535717559,"author":{"id":"3581901536452783","authorId":"3581901536452783","name":"Imeeng","avatar":"https://static.tigerbbs.com/e0aed7968b9134b940bf67762a13c6ea","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581901536452783","idStr":"3581901536452783"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NVAX\">$Novavax(NVAX)$</a>Die Liao","listText":"<a href=\"https://ttm.financial/S/NVAX\">$Novavax(NVAX)$</a>Die Liao","text":"$Novavax(NVAX)$Die Liao","images":[{"img":"https://community-static.tradeup.com/news/db54022310cc98f9f33e5365a8839369","width":"1284","height":"2538"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9999447012","isVote":1,"tweetType":1,"viewCount":3451,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9990179280,"gmtCreate":1660316048843,"gmtModify":1676533449916,"author":{"id":"3581901536452783","authorId":"3581901536452783","name":"Imeeng","avatar":"https://static.tigerbbs.com/e0aed7968b9134b940bf67762a13c6ea","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581901536452783","idStr":"3581901536452783"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/INMD\">$InMode Ltd.(INMD)$</a>Up up up","listText":"<a href=\"https://ttm.financial/S/INMD\">$InMode Ltd.(INMD)$</a>Up up up","text":"$InMode Ltd.(INMD)$Up up up","images":[{"img":"https://community-static.tradeup.com/news/2ff3e252090d20f786c0de9f901f50b9","width":"1284","height":"2538"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9990179280","isVote":1,"tweetType":1,"viewCount":2904,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9907468678,"gmtCreate":1660233588996,"gmtModify":1676529827100,"author":{"id":"3581901536452783","authorId":"3581901536452783","name":"Imeeng","avatar":"https://static.tigerbbs.com/e0aed7968b9134b940bf67762a13c6ea","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581901536452783","idStr":"3581901536452783"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/XPEV\">$XPeng Inc.(XPEV)$</a>🤓🤓🤓🤓🤓","listText":"<a href=\"https://ttm.financial/S/XPEV\">$XPeng Inc.(XPEV)$</a>🤓🤓🤓🤓🤓","text":"$XPeng Inc.(XPEV)$🤓🤓🤓🤓🤓","images":[{"img":"https://community-static.tradeup.com/news/c9294c23b46dde2952543dd5b08ec3c7","width":"1284","height":"4047"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9907468678","isVote":1,"tweetType":1,"viewCount":2459,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9907330007,"gmtCreate":1660139574912,"gmtModify":1703478310316,"author":{"id":"3581901536452783","authorId":"3581901536452783","name":"Imeeng","avatar":"https://static.tigerbbs.com/e0aed7968b9134b940bf67762a13c6ea","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581901536452783","idStr":"3581901536452783"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/INMD\">$InMode Ltd.(INMD)$</a>😫😫😫😫","listText":"<a href=\"https://ttm.financial/S/INMD\">$InMode Ltd.(INMD)$</a>😫😫😫😫","text":"$InMode Ltd.(INMD)$😫😫😫😫","images":[{"img":"https://community-static.tradeup.com/news/b00240963bb910dcaa72115b21e8d329","width":"1284","height":"2538"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9907330007","isVote":1,"tweetType":1,"viewCount":3203,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9902190923,"gmtCreate":1659658087164,"gmtModify":1705407844145,"author":{"id":"3581901536452783","authorId":"3581901536452783","name":"Imeeng","avatar":"https://static.tigerbbs.com/e0aed7968b9134b940bf67762a13c6ea","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581901536452783","idStr":"3581901536452783"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NVAX\">$Novavax(NVAX)$</a>#fightning","listText":"<a href=\"https://ttm.financial/S/NVAX\">$Novavax(NVAX)$</a>#fightning","text":"$Novavax(NVAX)$#fightning","images":[{"img":"https://community-static.tradeup.com/news/9dbbaf119fb1eca427ad33d48b9ed1bf","width":"1284","height":"4314"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9902190923","isVote":1,"tweetType":1,"viewCount":2371,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9901070533,"gmtCreate":1659104522222,"gmtModify":1676536258258,"author":{"id":"3581901536452783","authorId":"3581901536452783","name":"Imeeng","avatar":"https://static.tigerbbs.com/e0aed7968b9134b940bf67762a13c6ea","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581901536452783","idStr":"3581901536452783"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/INMD\">$InMode Ltd.(INMD)$</a>faints","listText":"<a href=\"https://ttm.financial/S/INMD\">$InMode Ltd.(INMD)$</a>faints","text":"$InMode Ltd.(INMD)$faints","images":[{"img":"https://community-static.tradeup.com/news/174c27a6a0790505f734e334c722bc09","width":"1284","height":"2538"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9901070533","isVote":1,"tweetType":1,"viewCount":2647,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9074439026,"gmtCreate":1658385968765,"gmtModify":1676536151471,"author":{"id":"3581901536452783","authorId":"3581901536452783","name":"Imeeng","avatar":"https://static.tigerbbs.com/e0aed7968b9134b940bf67762a13c6ea","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581901536452783","idStr":"3581901536452783"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NVAX\">$Novavax(NVAX)$</a>#fightning","listText":"<a href=\"https://ttm.financial/S/NVAX\">$Novavax(NVAX)$</a>#fightning","text":"$Novavax(NVAX)$#fightning","images":[{"img":"https://community-static.tradeup.com/news/7cd8e03cff82c649eb68a59b887f1b8f","width":"1284","height":"3275"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9074439026","isVote":1,"tweetType":1,"viewCount":3051,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9074009669,"gmtCreate":1658273756951,"gmtModify":1676536130885,"author":{"id":"3581901536452783","authorId":"3581901536452783","name":"Imeeng","avatar":"https://static.tigerbbs.com/e0aed7968b9134b940bf67762a13c6ea","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581901536452783","idStr":"3581901536452783"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/FIGS\">$FIGS, Inc.(FIGS)$</a>Steady bull run!!!","listText":"<a href=\"https://ttm.financial/S/FIGS\">$FIGS, Inc.(FIGS)$</a>Steady bull run!!!","text":"$FIGS, Inc.(FIGS)$Steady bull run!!!","images":[{"img":"https://community-static.tradeup.com/news/569e6c53624adcebcd72e758405aac01","width":"1284","height":"3185"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9074009669","isVote":1,"tweetType":1,"viewCount":2251,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9074000731,"gmtCreate":1658273725923,"gmtModify":1676536130869,"author":{"id":"3581901536452783","authorId":"3581901536452783","name":"Imeeng","avatar":"https://static.tigerbbs.com/e0aed7968b9134b940bf67762a13c6ea","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581901536452783","idStr":"3581901536452783"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NVAX\">$Novavax(NVAX)$</a>[Spurting]&nbsp;[Spurting]&nbsp;","listText":"<a href=\"https://ttm.financial/S/NVAX\">$Novavax(NVAX)$</a>[Spurting]&nbsp;[Spurting]&nbsp;","text":"$Novavax(NVAX)$[Spurting] [Spurting]","images":[{"img":"https://community-static.tradeup.com/news/78743205df2a990f95ac64a50ee85488","width":"1284","height":"2778"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9074000731","isVote":1,"tweetType":1,"viewCount":2881,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9075852569,"gmtCreate":1658188186451,"gmtModify":1676536118040,"author":{"id":"3581901536452783","authorId":"3581901536452783","name":"Imeeng","avatar":"https://static.tigerbbs.com/e0aed7968b9134b940bf67762a13c6ea","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581901536452783","idStr":"3581901536452783"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/XPEV\">$XPeng Inc.(XPEV)$</a>Can consider??","listText":"<a href=\"https://ttm.financial/S/XPEV\">$XPeng Inc.(XPEV)$</a>Can consider??","text":"$XPeng Inc.(XPEV)$Can consider??","images":[{"img":"https://community-static.tradeup.com/news/f3975acdf4fc3b4ad7f2365f2d9b6dea","width":"1284","height":"3365"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9075852569","isVote":1,"tweetType":1,"viewCount":2215,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9075851591,"gmtCreate":1658188040414,"gmtModify":1676536117956,"author":{"id":"3581901536452783","authorId":"3581901536452783","name":"Imeeng","avatar":"https://static.tigerbbs.com/e0aed7968b9134b940bf67762a13c6ea","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581901536452783","idStr":"3581901536452783"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NVAX\">$Novavax(NVAX)$</a>🫠🫠🫠","listText":"<a href=\"https://ttm.financial/S/NVAX\">$Novavax(NVAX)$</a>🫠🫠🫠","text":"$Novavax(NVAX)$🫠🫠🫠","images":[{"img":"https://community-static.tradeup.com/news/f35e815c93ee2a288ea87a74cd8fb69d","width":"1284","height":"2538"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9075851591","isVote":1,"tweetType":1,"viewCount":1030,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9072090248,"gmtCreate":1657928774184,"gmtModify":1676536081898,"author":{"id":"3581901536452783","authorId":"3581901536452783","name":"Imeeng","avatar":"https://static.tigerbbs.com/e0aed7968b9134b940bf67762a13c6ea","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581901536452783","idStr":"3581901536452783"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NVAX\">$Novavax(NVAX)$</a>😕😫😫😫","listText":"<a href=\"https://ttm.financial/S/NVAX\">$Novavax(NVAX)$</a>😕😫😫😫","text":"$Novavax(NVAX)$😕😫😫😫","images":[{"img":"https://community-static.tradeup.com/news/d37fe827e717d78837dfd97ce9cbe0f3","width":"1284","height":"2538"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9072090248","isVote":1,"tweetType":1,"viewCount":1113,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9044348572,"gmtCreate":1656719468396,"gmtModify":1676535881546,"author":{"id":"3581901536452783","authorId":"3581901536452783","name":"Imeeng","avatar":"https://static.tigerbbs.com/e0aed7968b9134b940bf67762a13c6ea","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581901536452783","idStr":"3581901536452783"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NVAX\">$Novavax(NVAX)$</a>sad","listText":"<a href=\"https://ttm.financial/S/NVAX\">$Novavax(NVAX)$</a>sad","text":"$Novavax(NVAX)$sad","images":[{"img":"https://community-static.tradeup.com/news/c2e36b9967dcc6051911a66e27543a0b","width":"1284","height":"2538"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9044348572","isVote":1,"tweetType":1,"viewCount":998,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9041605470,"gmtCreate":1656038507790,"gmtModify":1676535756412,"author":{"id":"3581901536452783","authorId":"3581901536452783","name":"Imeeng","avatar":"https://static.tigerbbs.com/e0aed7968b9134b940bf67762a13c6ea","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581901536452783","idStr":"3581901536452783"},"themes":[],"htmlText":"#fightning!","listText":"#fightning!","text":"#fightning!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9041605470","repostId":"9041344887","repostType":1,"repost":{"id":9041344887,"gmtCreate":1656024905549,"gmtModify":1676535750703,"author":{"id":"3576339097425722","authorId":"3576339097425722","name":"Asphen","avatar":"https://community-static.tradeup.com/news/55ff1b64b2787933c17d863ecae83f09","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3576339097425722","idStr":"3576339097425722"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/INMD\">$InMode Ltd.(INMD)$</a>INMD - Has built a bottom; Unlikely to drop below 21.&nbsp;Needs to clear 24 first.&nbsp;If break 27, relative ease until 34.<a href=\"https://ttm.financial/U/9000000000000149\">@TigerStars</a><a href=\"https://ttm.financial/U/3579604268396746\">@Darrenlee11</a><a href=\"https://ttm.financial/U/3579132585127677\">@YTiong</a><a href=\"https://ttm.financial/U/3577700186071729\">@Deposit</a>","listText":"<a href=\"https://ttm.financial/S/INMD\">$InMode Ltd.(INMD)$</a>INMD - Has built a bottom; Unlikely to drop below 21.&nbsp;Needs to clear 24 first.&nbsp;If break 27, relative ease until 34.<a href=\"https://ttm.financial/U/9000000000000149\">@TigerStars</a><a href=\"https://ttm.financial/U/3579604268396746\">@Darrenlee11</a><a href=\"https://ttm.financial/U/3579132585127677\">@YTiong</a><a href=\"https://ttm.financial/U/3577700186071729\">@Deposit</a>","text":"$InMode Ltd.(INMD)$INMD - Has built a bottom; Unlikely to drop below 21. Needs to clear 24 first. If break 27, relative ease until 34.@TigerStars@Darrenlee11@YTiong@Deposit","images":[{"img":"https://community-static.tradeup.com/news/579d8ca41191004cce024c37babeb3ab","width":"2280","height":"1080"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9041344887","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":788,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9009831115,"gmtCreate":1640600012165,"gmtModify":1676533528271,"author":{"id":"3581901536452783","authorId":"3581901536452783","name":"Imeeng","avatar":"https://static.tigerbbs.com/e0aed7968b9134b940bf67762a13c6ea","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581901536452783","idStr":"3581901536452783"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NVAX\">$Novavax(NVAX)$</a>pls like","listText":"<a href=\"https://ttm.financial/S/NVAX\">$Novavax(NVAX)$</a>pls like","text":"$Novavax(NVAX)$pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9009831115","isVote":1,"tweetType":1,"viewCount":1271,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":861029771,"gmtCreate":1632443674393,"gmtModify":1676530783444,"author":{"id":"3581901536452783","authorId":"3581901536452783","name":"Imeeng","avatar":"https://static.tigerbbs.com/e0aed7968b9134b940bf67762a13c6ea","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581901536452783","idStr":"3581901536452783"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/861029771","repostId":"2169695648","repostType":2,"repost":{"id":"2169695648","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1632428141,"share":"https://ttm.financial/m/news/2169695648?lang=en_US&edition=fundamental","pubTime":"2021-09-24 04:15","market":"hk","language":"en","title":"Nike Q1 EPS $1.16 Beats $1.11 Estimate, Sales $12.20B Miss $12.46B Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2169695648","media":"Benzinga","summary":"Nike (NYSE:NKE) reported quarterly earnings of $1.16 per share which beat the analyst consensus estimate of $1.11 by 4.5 percent. This is a 22.11 percent increase over earnings of $0.95 per share from the same period","content":"<html><body><p>Nike (NYSE:NKE) reported quarterly earnings of $1.16 per share which beat the analyst consensus estimate of $1.11 by 4.5 percent. This is a 22.11 percent increase over earnings of $0.95 per share from the same period last year.  The company reported quarterly sales of $12.20 billion which missed the analyst consensus estimate of $12.46 billion by 2.09 percent.  This is a 15.16 percent increase over sales of $10.59 billion the same period last year.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nike Q1 EPS $1.16 Beats $1.11 Estimate, Sales $12.20B Miss $12.46B Estimate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNike Q1 EPS $1.16 Beats $1.11 Estimate, Sales $12.20B Miss $12.46B Estimate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-09-24 04:15</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Nike (NYSE:NKE) reported quarterly earnings of $1.16 per share which beat the analyst consensus estimate of $1.11 by 4.5 percent. This is a 22.11 percent increase over earnings of $0.95 per share from the same period last year.  The company reported quarterly sales of $12.20 billion which missed the analyst consensus estimate of $12.46 billion by 2.09 percent.  This is a 15.16 percent increase over sales of $10.59 billion the same period last year.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NKE":"耐克"},"source_url":"https://www.benzinga.com/news/earnings/21/09/23080496/nike-q1-eps-1-16-beats-1-11-estimate-sales-12-20b-miss-12-46b-estimate","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2169695648","content_text":"Nike (NYSE:NKE) reported quarterly earnings of $1.16 per share which beat the analyst consensus estimate of $1.11 by 4.5 percent. This is a 22.11 percent increase over earnings of $0.95 per share from the same period last year.  The company reported quarterly sales of $12.20 billion which missed the analyst consensus estimate of $12.46 billion by 2.09 percent.  This is a 15.16 percent increase over sales of $10.59 billion the same period last year.","news_type":1,"symbols_score_info":{"NKE":1}},"isVote":1,"tweetType":1,"viewCount":847,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":863946052,"gmtCreate":1632355414276,"gmtModify":1676530759845,"author":{"id":"3581901536452783","authorId":"3581901536452783","name":"Imeeng","avatar":"https://static.tigerbbs.com/e0aed7968b9134b940bf67762a13c6ea","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581901536452783","idStr":"3581901536452783"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>won’t cut losses yet","listText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>won’t cut losses yet","text":"$Alibaba(BABA)$won’t cut losses yet","images":[{"img":"https://static.tigerbbs.com/b366aafad45dcba92bd4f6ca7dcf113a","width":"1284","height":"2223"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/863946052","isVote":1,"tweetType":1,"viewCount":1126,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":869911715,"gmtCreate":1632234478937,"gmtModify":1676530731291,"author":{"id":"3581901536452783","authorId":"3581901536452783","name":"Imeeng","avatar":"https://static.tigerbbs.com/e0aed7968b9134b940bf67762a13c6ea","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581901536452783","idStr":"3581901536452783"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>Kept dropping…","listText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>Kept dropping…","text":"$Alibaba(BABA)$Kept dropping…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/869911715","isVote":1,"tweetType":1,"viewCount":879,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885891525,"gmtCreate":1631773142967,"gmtModify":1676530631893,"author":{"id":"3581901536452783","authorId":"3581901536452783","name":"Imeeng","avatar":"https://static.tigerbbs.com/e0aed7968b9134b940bf67762a13c6ea","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581901536452783","idStr":"3581901536452783"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/885891525","repostId":"1189685868","repostType":4,"repost":{"id":"1189685868","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1631714905,"share":"https://ttm.financial/m/news/1189685868?lang=en_US&edition=fundamental","pubTime":"2021-09-15 22:08","market":"us","language":"en","title":"BioNTech SE stock jumped 4% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1189685868","media":"Tiger Newspress","summary":"BioNTech SE stock jumped 4% in morning trading as Pfizer said booster shots of vaccine restore wanin","content":"<p>BioNTech SE stock jumped&nbsp;4% in morning trading&nbsp;as&nbsp;Pfizer said booster shots of vaccine restore waning Immunity.Pfizer shares&nbsp;rose&nbsp;0.7%.</p>\n<p><img src=\"https://static.tigerbbs.com/fb4c307ca1b61c145bfb12a955ecf588\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>\n<p>Pfizer Inc.&nbsp;said that data from the U.S. and Israel suggest that the efficacy of its Covid-19 vaccine wanes over time, and that a booster dose was safe and effective at warding off the virus and new variants.</p>\n<p>The company detailed the data in a&nbsp;presentation&nbsp;it will deliver to a meeting of outside advisers to the Food and Drug Administration on Friday. The panel is expected to make recommendations for whether more Americans should receive booster shots.</p>\n<p>“Real-world data from Israel and the United States suggest that rates of breakthrough infections are rising faster in individuals who were vaccinated earlier,” Pfizer said in its presentation, which was posted on the FDA website. The drug giant is partnering with Germany’s&nbsp;BioNTech SE&nbsp;to make the shots.</p>\n<p>The decrease in effectiveness is “primarily due to waning of vaccine immune responses over time,” rather than the delta variant, Pfizer researchers said in the presentation.</p>\n<p><b>Unpublished Data</b></p>\n<p>According to a meeting&nbsp;agenda&nbsp;the FDA posted on its website, in addition to the Pfizer presentation, the Friday panel will include presentations from the Centers for Disease Control and Prevention, FDA staff and researchers from Israel and the U.K.</p>\n<p>The Israel officials will present data from that country on booster protection against infections and severe disease, according to the agenda, and a professor of medical statistics from the University of Bristol will present data on real-world vaccine effectiveness.</p>\n<p>While its vaccine continues to provide strong protection against hospitalizations and severe disease in the U.S., Pfizer said, data from Israel and elsewhere suggests that reduction in efficacy against infection may be followed by reduced effectiveness against severe disease, especially among vulnerable elderly people.</p>\n<p>Early unpublished data from an Israeli health maintenance organization suggest that a third booster dose is highly effective in areas where the delta variant is dominant, according to the Pfizer document. Giving a third dose to people more than 60 years old was associated with 86% effectiveness against testing positive for Covid starting at least a week after the booster, Pfizer said.</p>\n<p>Pfizer also detailed immune response results from a final-stage trial of booster shots in over 300 people, showing that a third dose bolstered blood antibody levels. One month after the third dose, levels of the protective antibodies were more than triple what they had been a month after the second shot.</p>\n<p>No new unexpected side effects were identified from safety data associated with boosters in the final-stage study, according to the Pfizer report. Consideration of a booster dose six months after a second dose of its shot is warranted, based on similarities between the outbreaks in Israel and the U.S., Pfizer said.</p>\n<p><b>Signs of Friction</b></p>\n<p>Marion Gruber, one of two top vaccine officials who FDA recently said will step down later this year, is also scheduled to speak. Gruber was co-author of an article in The Lancet earlier this week arguing that booster shots weren’t yet necessary for most people. The departures of the two longtime agency staff are a potential sign of friction over the Biden booster plan.</p>\n<p>The FDA hasn’t yet posted its staff report on the booster data. The agency’s documents are typically released 48 hours before the start of a panel meeting.</p>\n<p>The FDA is working as quickly as possible to post the items throughout the day as they are finalized and available, spokesperson Alison Hunt said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech SE stock jumped 4% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech SE stock jumped 4% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-09-15 22:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BioNTech SE stock jumped&nbsp;4% in morning trading&nbsp;as&nbsp;Pfizer said booster shots of vaccine restore waning Immunity.Pfizer shares&nbsp;rose&nbsp;0.7%.</p>\n<p><img src=\"https://static.tigerbbs.com/fb4c307ca1b61c145bfb12a955ecf588\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>\n<p>Pfizer Inc.&nbsp;said that data from the U.S. and Israel suggest that the efficacy of its Covid-19 vaccine wanes over time, and that a booster dose was safe and effective at warding off the virus and new variants.</p>\n<p>The company detailed the data in a&nbsp;presentation&nbsp;it will deliver to a meeting of outside advisers to the Food and Drug Administration on Friday. The panel is expected to make recommendations for whether more Americans should receive booster shots.</p>\n<p>“Real-world data from Israel and the United States suggest that rates of breakthrough infections are rising faster in individuals who were vaccinated earlier,” Pfizer said in its presentation, which was posted on the FDA website. The drug giant is partnering with Germany’s&nbsp;BioNTech SE&nbsp;to make the shots.</p>\n<p>The decrease in effectiveness is “primarily due to waning of vaccine immune responses over time,” rather than the delta variant, Pfizer researchers said in the presentation.</p>\n<p><b>Unpublished Data</b></p>\n<p>According to a meeting&nbsp;agenda&nbsp;the FDA posted on its website, in addition to the Pfizer presentation, the Friday panel will include presentations from the Centers for Disease Control and Prevention, FDA staff and researchers from Israel and the U.K.</p>\n<p>The Israel officials will present data from that country on booster protection against infections and severe disease, according to the agenda, and a professor of medical statistics from the University of Bristol will present data on real-world vaccine effectiveness.</p>\n<p>While its vaccine continues to provide strong protection against hospitalizations and severe disease in the U.S., Pfizer said, data from Israel and elsewhere suggests that reduction in efficacy against infection may be followed by reduced effectiveness against severe disease, especially among vulnerable elderly people.</p>\n<p>Early unpublished data from an Israeli health maintenance organization suggest that a third booster dose is highly effective in areas where the delta variant is dominant, according to the Pfizer document. Giving a third dose to people more than 60 years old was associated with 86% effectiveness against testing positive for Covid starting at least a week after the booster, Pfizer said.</p>\n<p>Pfizer also detailed immune response results from a final-stage trial of booster shots in over 300 people, showing that a third dose bolstered blood antibody levels. One month after the third dose, levels of the protective antibodies were more than triple what they had been a month after the second shot.</p>\n<p>No new unexpected side effects were identified from safety data associated with boosters in the final-stage study, according to the Pfizer report. Consideration of a booster dose six months after a second dose of its shot is warranted, based on similarities between the outbreaks in Israel and the U.S., Pfizer said.</p>\n<p><b>Signs of Friction</b></p>\n<p>Marion Gruber, one of two top vaccine officials who FDA recently said will step down later this year, is also scheduled to speak. Gruber was co-author of an article in The Lancet earlier this week arguing that booster shots weren’t yet necessary for most people. The departures of the two longtime agency staff are a potential sign of friction over the Biden booster plan.</p>\n<p>The FDA hasn’t yet posted its staff report on the booster data. The agency’s documents are typically released 48 hours before the start of a panel meeting.</p>\n<p>The FDA is working as quickly as possible to post the items throughout the day as they are finalized and available, spokesperson Alison Hunt said.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1189685868","content_text":"BioNTech SE stock jumped 4% in morning trading as Pfizer said booster shots of vaccine restore waning Immunity.Pfizer shares rose 0.7%.\n\nPfizer Inc. said that data from the U.S. and Israel suggest that the efficacy of its Covid-19 vaccine wanes over time, and that a booster dose was safe and effective at warding off the virus and new variants.\nThe company detailed the data in a presentation it will deliver to a meeting of outside advisers to the Food and Drug Administration on Friday. The panel is expected to make recommendations for whether more Americans should receive booster shots.\n“Real-world data from Israel and the United States suggest that rates of breakthrough infections are rising faster in individuals who were vaccinated earlier,” Pfizer said in its presentation, which was posted on the FDA website. The drug giant is partnering with Germany’s BioNTech SE to make the shots.\nThe decrease in effectiveness is “primarily due to waning of vaccine immune responses over time,” rather than the delta variant, Pfizer researchers said in the presentation.\nUnpublished Data\nAccording to a meeting agenda the FDA posted on its website, in addition to the Pfizer presentation, the Friday panel will include presentations from the Centers for Disease Control and Prevention, FDA staff and researchers from Israel and the U.K.\nThe Israel officials will present data from that country on booster protection against infections and severe disease, according to the agenda, and a professor of medical statistics from the University of Bristol will present data on real-world vaccine effectiveness.\nWhile its vaccine continues to provide strong protection against hospitalizations and severe disease in the U.S., Pfizer said, data from Israel and elsewhere suggests that reduction in efficacy against infection may be followed by reduced effectiveness against severe disease, especially among vulnerable elderly people.\nEarly unpublished data from an Israeli health maintenance organization suggest that a third booster dose is highly effective in areas where the delta variant is dominant, according to the Pfizer document. Giving a third dose to people more than 60 years old was associated with 86% effectiveness against testing positive for Covid starting at least a week after the booster, Pfizer said.\nPfizer also detailed immune response results from a final-stage trial of booster shots in over 300 people, showing that a third dose bolstered blood antibody levels. One month after the third dose, levels of the protective antibodies were more than triple what they had been a month after the second shot.\nNo new unexpected side effects were identified from safety data associated with boosters in the final-stage study, according to the Pfizer report. Consideration of a booster dose six months after a second dose of its shot is warranted, based on similarities between the outbreaks in Israel and the U.S., Pfizer said.\nSigns of Friction\nMarion Gruber, one of two top vaccine officials who FDA recently said will step down later this year, is also scheduled to speak. Gruber was co-author of an article in The Lancet earlier this week arguing that booster shots weren’t yet necessary for most people. The departures of the two longtime agency staff are a potential sign of friction over the Biden booster plan.\nThe FDA hasn’t yet posted its staff report on the booster data. The agency’s documents are typically released 48 hours before the start of a panel meeting.\nThe FDA is working as quickly as possible to post the items throughout the day as they are finalized and available, spokesperson Alison Hunt said.","news_type":1,"symbols_score_info":{"BNTX":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":917,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":882588551,"gmtCreate":1631707601673,"gmtModify":1676530613845,"author":{"id":"3581901536452783","authorId":"3581901536452783","name":"Imeeng","avatar":"https://static.tigerbbs.com/e0aed7968b9134b940bf67762a13c6ea","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581901536452783","idStr":"3581901536452783"},"themes":[],"htmlText":"Perseverance!!","listText":"Perseverance!!","text":"Perseverance!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/882588551","repostId":"882581472","repostType":1,"repost":{"id":882581472,"gmtCreate":1631707507196,"gmtModify":1676530613829,"author":{"id":"3573375517846152","authorId":"3573375517846152","name":"Buythedip","avatar":"https://community-static.tradeup.com/news/e7905324638a15789f7ab478cba611c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573375517846152","idStr":"3573375517846152"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>Please la","listText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>Please la","text":"$Alibaba(BABA)$Please la","images":[{"img":"https://static.tigerbbs.com/ad3ecfe6655b6cb9c5d666b240df49fa","width":"1242","height":"2385"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/882581472","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":916,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":883711631,"gmtCreate":1631272748123,"gmtModify":1676530515160,"author":{"id":"3581901536452783","authorId":"3581901536452783","name":"Imeeng","avatar":"https://static.tigerbbs.com/e0aed7968b9134b940bf67762a13c6ea","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581901536452783","idStr":"3581901536452783"},"themes":[],"htmlText":"Buy At dip?","listText":"Buy At dip?","text":"Buy At dip?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883711631","repostId":"1158877090","repostType":2,"repost":{"id":"1158877090","kind":"news","pubTimestamp":1631259068,"share":"https://ttm.financial/m/news/1158877090?lang=en_US&edition=fundamental","pubTime":"2021-09-10 15:31","market":"us","language":"en","title":"Why Novavax Stock Slipped Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=1158877090","media":"Motley Fool","summary":"(Update: Sept 10, 2021 at 04:14 a.m. ET)\n\nAuthorization of the company's COVID-19 vaccine in India a","content":"<p><i><b>(Update: Sept 10, 2021 at 04:14 a.m. ET)</b></i></p>\n<blockquote>\n <b>Authorization of the company's COVID-19 vaccine in India appears to have hit a speed bump.</b>\n</blockquote>\n<p><b>Key Points</b></p>\n<ul>\n <li>A report stated that the Indian government has requested additional data for Novavax's COVID-19 vaccine candidate before it can grant Emergency Use Authorization.</li>\n <li>EUA for the vaccine in India was originally expected in October but will now be pushed back.</li>\n <li>The delay isn't a huge blow for Novavax with the company's bigger opportunities in developed markets.</li>\n</ul>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b> were slipping 2.6% lower as of 3:25 p.m. EDT on Thursday. The decline came following a report by&nbsp;<i>The Economic Times</i>&nbsp;that the Indian government has requested additional data from Novavax's partner, Serum Institute of India (SII), for COVID-19 vaccine candidate NVX-CoV2373 (which is called Covovax in India).</p>\n<p><b>So what</b></p>\n<p>SII filed for Emergency Use Authorization (EUA) in India for Covovax in August. This submission was based on data from international clinical studies. An official with the country's drug regulatory agency has asked for data from a clinical trial of the vaccine conducted in India, according to<i>The Economic Times</i>&nbsp;article.</p>\n<p>The problem is that SII likely won't be able to submit data from the clinical studies of Covovax in India until next month. SII CEO Adar Poonawalla stated in August that his organization hoped that the COVID-19 vaccine would be launched in India in October for adults and in the first quarter of 2022 for children. That timeline will now be pushed back.</p>\n<p>This delay isn't a huge blow for Novavax, as evidenced by the relatively small drop in thevaccine stock. The company's biggest opportunities are in developed markets including the U.S. and Europe.</p>\n<p><b>Now what</b></p>\n<p>Novavax expects to file for EUA for NVX-CoV2373 in the United Kingdom within the next few weeks. That filing should be quickly followed by submissions in Australia, New Zealand, and the European Union. The company remains on track to file for U.S. EUA in the fourth quarter of 2021.</p>\n<p>Novavax fell over 2% in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/d6cab4a5dd8795f7fda9bc597e6d9d98\" tg-width=\"996\" tg-height=\"568\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Novavax Stock Slipped Thursday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Novavax Stock Slipped Thursday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-10 15:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/why-novavax-stock-slipped-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Update: Sept 10, 2021 at 04:14 a.m. ET)\n\nAuthorization of the company's COVID-19 vaccine in India appears to have hit a speed bump.\n\nKey Points\n\nA report stated that the Indian government has ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/why-novavax-stock-slipped-today/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/09/09/why-novavax-stock-slipped-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1158877090","content_text":"(Update: Sept 10, 2021 at 04:14 a.m. ET)\n\nAuthorization of the company's COVID-19 vaccine in India appears to have hit a speed bump.\n\nKey Points\n\nA report stated that the Indian government has requested additional data for Novavax's COVID-19 vaccine candidate before it can grant Emergency Use Authorization.\nEUA for the vaccine in India was originally expected in October but will now be pushed back.\nThe delay isn't a huge blow for Novavax with the company's bigger opportunities in developed markets.\n\nWhat happened\nShares of Novavax were slipping 2.6% lower as of 3:25 p.m. EDT on Thursday. The decline came following a report by The Economic Times that the Indian government has requested additional data from Novavax's partner, Serum Institute of India (SII), for COVID-19 vaccine candidate NVX-CoV2373 (which is called Covovax in India).\nSo what\nSII filed for Emergency Use Authorization (EUA) in India for Covovax in August. This submission was based on data from international clinical studies. An official with the country's drug regulatory agency has asked for data from a clinical trial of the vaccine conducted in India, according toThe Economic Times article.\nThe problem is that SII likely won't be able to submit data from the clinical studies of Covovax in India until next month. SII CEO Adar Poonawalla stated in August that his organization hoped that the COVID-19 vaccine would be launched in India in October for adults and in the first quarter of 2022 for children. That timeline will now be pushed back.\nThis delay isn't a huge blow for Novavax, as evidenced by the relatively small drop in thevaccine stock. The company's biggest opportunities are in developed markets including the U.S. and Europe.\nNow what\nNovavax expects to file for EUA for NVX-CoV2373 in the United Kingdom within the next few weeks. That filing should be quickly followed by submissions in Australia, New Zealand, and the European Union. The company remains on track to file for U.S. EUA in the fourth quarter of 2021.\nNovavax fell over 2% in premarket trading.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":463,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":812644777,"gmtCreate":1630587294099,"gmtModify":1676530347914,"author":{"id":"3581901536452783","authorId":"3581901536452783","name":"Imeeng","avatar":"https://static.tigerbbs.com/e0aed7968b9134b940bf67762a13c6ea","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581901536452783","idStr":"3581901536452783"},"themes":[],"htmlText":"Market pls stay strong","listText":"Market pls stay strong","text":"Market pls stay strong","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/812644777","repostId":"1132731638","repostType":4,"repost":{"id":"1132731638","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1630584615,"share":"https://ttm.financial/m/news/1132731638?lang=en_US&edition=fundamental","pubTime":"2021-09-02 20:10","market":"us","language":"en","title":"Toplines Before US Market Open on Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=1132731638","media":"Tiger Newspress","summary":"U.S. stock index futures inched higher on Thursday on hopes the Federal Reserve would maintain an ac","content":"<p>U.S. stock index futures inched higher on Thursday on hopes the Federal Reserve would maintain an accommodative policy amid signs that a broader economic recovery was slowing.</p>\n<p>At 8:05 a.m. ET, Dow E-minis were up 63 points, or 0.18%, S&amp;P 500 E-minis were up 9.25 points, or 0.2% and Nasdaq 100 E-minis were up 45.5 points, or 0.29%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/065d8b0b6a7cc1992aaa1d2c32c609fc\" tg-width=\"916\" tg-height=\"290\" width=\"100%\" height=\"auto\"><span>*Source From Tiger Trade, EST 08:05</span></p>\n<p>Heavyweight technology stocks including Apple Inc, Netflix Inc and Amazon.com Inc, which tend to perform better when interest rates are low, were among the biggest gainers in premarket trading.</p>\n<p>Oil majors Exxon Mobil, Chevron Corp and Schlumberger NV also rose between 0.2% and 0.5%, tracking crude prices. [O/R]</p>\n<p>The S&amp;P 500 and the tech-heavy Nasdaq have consistently hit record highs over the past few weeks as a solid corporate earnings season underpinned confidence even as data showed the post-pandemic U.S. economic growth was beginning to slow.</p>\n<p>Still, strategists said those highs could be challenged as the rebound in corporate profits loses its edge and the pressure builds on the Fed to taper its massive stimulus.</p>\n<p><b>Stocks making the biggest moves in the premarket:</b></p>\n<p><a href=\"https://laohu8.com/S/HRL\">Hormel</a> – The food producer reported adjusted quarterly earnings of 39 cents per share, matching forecasts, with revenue coming in above estimates. However, Hormel gave a weaker-than-expected full-year outlook, noting the impact of higher costs, although it said price hikes and cost cuts should help its margins moving forward. Hormel fell 3.5% in premarket trading.</p>\n<p><a href=\"https://laohu8.com/S/LE\">Lands' End</a> – The apparel retailer beat estimates by 6 cents with quarterly earnings of 48 cents per share and revenue above estimates as well. However, the company also said its profit margins would moderate in the back half of its fiscal year due to supply chain challenges, and the stock fell 3% in premarket action.</p>\n<p><a href=\"https://laohu8.com/S/HRC\">Hill-Rom</a> – The medical equipment maker agreed to be bought by medical products makerBaxter International(BAX) for $156 per share in cash or about $10.5 billion. It had been reported earlier this week that the two sides were in talks about a potential $10 billion deal. Hill-Rom gained 3.1% in premarket trading, while Baxter edged higher by 0.7%.</p>\n<p><a href=\"https://laohu8.com/S/SIG\">Signet Jewelers</a> – The jewelry retailer reported adjusted quarterly earnings of $3.57 per share, well above the consensus estimate of $1.69, with revenue exceeding forecasts as well. Comparable store sales surged 97%, more than the 79.2% increase that analysts were anticipating. Signet also raised its full-year outlook, and its stock rallied 5.4% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/CHWY\">Chewy, Inc.</a> – Chewy tumbled 10.2% in the premarket, following a wider-than-expected quarterly loss and revenue that fell slightly short of estimates. The pet products retailer’s adjusted loss of 4 cents per share was twice as wide as analysts had anticipated, with Chewy noting a higher-than-usual level of out-of-stock products. The company also issued a weaker-than-expected outlook.</p>\n<p><a href=\"https://laohu8.com/S/CHPT\">ChargePoint Holdings Inc.</a> – The electric vehicle charging company saw its shares soar 12.3% in the premarket after quarterly sales beat estimates and the company raised its full-year revenue guidance. For its most recent quarter, ChargePoint matched Street forecasts with an adjusted loss of 13 cents per share.</p>\n<p><a href=\"https://laohu8.com/S/OKTA\">Okta Inc.</a> – The identity management software company posted an adjusted quarterly loss of 11 cents per share, smaller than the 35-cent loss that analysts were anticipating. Revenue came in above estimates, and the company issued a better-than-expected outlook, but the shares fell 1.5% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/AI\">C3.ai, Inc.</a> – The artificial intelligence software provider’s stock tumbled 7.7% in premarket trading after it reported a surprise quarterly loss. C3.ai lost an adjusted 37 cents per share for its latest quarter, compared with analyst forecasts of a 28 cents per share profit, and it also issued a weaker-than-expected current-quarter revenue outlook.</p>\n<p><a href=\"https://laohu8.com/S/FIVE\">Five Below</a> – The discount retailer saw its stock slide 8.6% in the premarket, despite a 4-cent beat with quarterly earnings of $1.15 per share. Five Below’s revenue was shy of Street forecasts, and it is not giving sales or earnings guidance for the full year due to uncertainties surrounding Covid-19.</p>\n<p><a href=\"https://laohu8.com/S/CIEN\">Ciena</a> – The networking equipment maker earned an adjusted 92 cents per share for its latest quarter, beating estimates by 13 cents, while revenue beat estimates as well amid what the company calls “robust demand.” Separately, Ciena announced the acquisition ofAT&amp;T’s (T) Vyatta virtual routing and switching technology unit. Ciena jumped 6.3% in premarket trading.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Thursday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Thursday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-09-02 20:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>U.S. stock index futures inched higher on Thursday on hopes the Federal Reserve would maintain an accommodative policy amid signs that a broader economic recovery was slowing.</p>\n<p>At 8:05 a.m. ET, Dow E-minis were up 63 points, or 0.18%, S&amp;P 500 E-minis were up 9.25 points, or 0.2% and Nasdaq 100 E-minis were up 45.5 points, or 0.29%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/065d8b0b6a7cc1992aaa1d2c32c609fc\" tg-width=\"916\" tg-height=\"290\" width=\"100%\" height=\"auto\"><span>*Source From Tiger Trade, EST 08:05</span></p>\n<p>Heavyweight technology stocks including Apple Inc, Netflix Inc and Amazon.com Inc, which tend to perform better when interest rates are low, were among the biggest gainers in premarket trading.</p>\n<p>Oil majors Exxon Mobil, Chevron Corp and Schlumberger NV also rose between 0.2% and 0.5%, tracking crude prices. [O/R]</p>\n<p>The S&amp;P 500 and the tech-heavy Nasdaq have consistently hit record highs over the past few weeks as a solid corporate earnings season underpinned confidence even as data showed the post-pandemic U.S. economic growth was beginning to slow.</p>\n<p>Still, strategists said those highs could be challenged as the rebound in corporate profits loses its edge and the pressure builds on the Fed to taper its massive stimulus.</p>\n<p><b>Stocks making the biggest moves in the premarket:</b></p>\n<p><a href=\"https://laohu8.com/S/HRL\">Hormel</a> – The food producer reported adjusted quarterly earnings of 39 cents per share, matching forecasts, with revenue coming in above estimates. However, Hormel gave a weaker-than-expected full-year outlook, noting the impact of higher costs, although it said price hikes and cost cuts should help its margins moving forward. Hormel fell 3.5% in premarket trading.</p>\n<p><a href=\"https://laohu8.com/S/LE\">Lands' End</a> – The apparel retailer beat estimates by 6 cents with quarterly earnings of 48 cents per share and revenue above estimates as well. However, the company also said its profit margins would moderate in the back half of its fiscal year due to supply chain challenges, and the stock fell 3% in premarket action.</p>\n<p><a href=\"https://laohu8.com/S/HRC\">Hill-Rom</a> – The medical equipment maker agreed to be bought by medical products makerBaxter International(BAX) for $156 per share in cash or about $10.5 billion. It had been reported earlier this week that the two sides were in talks about a potential $10 billion deal. Hill-Rom gained 3.1% in premarket trading, while Baxter edged higher by 0.7%.</p>\n<p><a href=\"https://laohu8.com/S/SIG\">Signet Jewelers</a> – The jewelry retailer reported adjusted quarterly earnings of $3.57 per share, well above the consensus estimate of $1.69, with revenue exceeding forecasts as well. Comparable store sales surged 97%, more than the 79.2% increase that analysts were anticipating. Signet also raised its full-year outlook, and its stock rallied 5.4% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/CHWY\">Chewy, Inc.</a> – Chewy tumbled 10.2% in the premarket, following a wider-than-expected quarterly loss and revenue that fell slightly short of estimates. The pet products retailer’s adjusted loss of 4 cents per share was twice as wide as analysts had anticipated, with Chewy noting a higher-than-usual level of out-of-stock products. The company also issued a weaker-than-expected outlook.</p>\n<p><a href=\"https://laohu8.com/S/CHPT\">ChargePoint Holdings Inc.</a> – The electric vehicle charging company saw its shares soar 12.3% in the premarket after quarterly sales beat estimates and the company raised its full-year revenue guidance. For its most recent quarter, ChargePoint matched Street forecasts with an adjusted loss of 13 cents per share.</p>\n<p><a href=\"https://laohu8.com/S/OKTA\">Okta Inc.</a> – The identity management software company posted an adjusted quarterly loss of 11 cents per share, smaller than the 35-cent loss that analysts were anticipating. Revenue came in above estimates, and the company issued a better-than-expected outlook, but the shares fell 1.5% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/AI\">C3.ai, Inc.</a> – The artificial intelligence software provider’s stock tumbled 7.7% in premarket trading after it reported a surprise quarterly loss. C3.ai lost an adjusted 37 cents per share for its latest quarter, compared with analyst forecasts of a 28 cents per share profit, and it also issued a weaker-than-expected current-quarter revenue outlook.</p>\n<p><a href=\"https://laohu8.com/S/FIVE\">Five Below</a> – The discount retailer saw its stock slide 8.6% in the premarket, despite a 4-cent beat with quarterly earnings of $1.15 per share. Five Below’s revenue was shy of Street forecasts, and it is not giving sales or earnings guidance for the full year due to uncertainties surrounding Covid-19.</p>\n<p><a href=\"https://laohu8.com/S/CIEN\">Ciena</a> – The networking equipment maker earned an adjusted 92 cents per share for its latest quarter, beating estimates by 13 cents, while revenue beat estimates as well amid what the company calls “robust demand.” Separately, Ciena announced the acquisition ofAT&amp;T’s (T) Vyatta virtual routing and switching technology unit. Ciena jumped 6.3% in premarket trading.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1132731638","content_text":"U.S. stock index futures inched higher on Thursday on hopes the Federal Reserve would maintain an accommodative policy amid signs that a broader economic recovery was slowing.\nAt 8:05 a.m. ET, Dow E-minis were up 63 points, or 0.18%, S&P 500 E-minis were up 9.25 points, or 0.2% and Nasdaq 100 E-minis were up 45.5 points, or 0.29%.\n*Source From Tiger Trade, EST 08:05\nHeavyweight technology stocks including Apple Inc, Netflix Inc and Amazon.com Inc, which tend to perform better when interest rates are low, were among the biggest gainers in premarket trading.\nOil majors Exxon Mobil, Chevron Corp and Schlumberger NV also rose between 0.2% and 0.5%, tracking crude prices. [O/R]\nThe S&P 500 and the tech-heavy Nasdaq have consistently hit record highs over the past few weeks as a solid corporate earnings season underpinned confidence even as data showed the post-pandemic U.S. economic growth was beginning to slow.\nStill, strategists said those highs could be challenged as the rebound in corporate profits loses its edge and the pressure builds on the Fed to taper its massive stimulus.\nStocks making the biggest moves in the premarket:\nHormel – The food producer reported adjusted quarterly earnings of 39 cents per share, matching forecasts, with revenue coming in above estimates. However, Hormel gave a weaker-than-expected full-year outlook, noting the impact of higher costs, although it said price hikes and cost cuts should help its margins moving forward. Hormel fell 3.5% in premarket trading.\nLands' End – The apparel retailer beat estimates by 6 cents with quarterly earnings of 48 cents per share and revenue above estimates as well. However, the company also said its profit margins would moderate in the back half of its fiscal year due to supply chain challenges, and the stock fell 3% in premarket action.\nHill-Rom – The medical equipment maker agreed to be bought by medical products makerBaxter International(BAX) for $156 per share in cash or about $10.5 billion. It had been reported earlier this week that the two sides were in talks about a potential $10 billion deal. Hill-Rom gained 3.1% in premarket trading, while Baxter edged higher by 0.7%.\nSignet Jewelers – The jewelry retailer reported adjusted quarterly earnings of $3.57 per share, well above the consensus estimate of $1.69, with revenue exceeding forecasts as well. Comparable store sales surged 97%, more than the 79.2% increase that analysts were anticipating. Signet also raised its full-year outlook, and its stock rallied 5.4% in the premarket.\nChewy, Inc. – Chewy tumbled 10.2% in the premarket, following a wider-than-expected quarterly loss and revenue that fell slightly short of estimates. The pet products retailer’s adjusted loss of 4 cents per share was twice as wide as analysts had anticipated, with Chewy noting a higher-than-usual level of out-of-stock products. The company also issued a weaker-than-expected outlook.\nChargePoint Holdings Inc. – The electric vehicle charging company saw its shares soar 12.3% in the premarket after quarterly sales beat estimates and the company raised its full-year revenue guidance. For its most recent quarter, ChargePoint matched Street forecasts with an adjusted loss of 13 cents per share.\nOkta Inc. – The identity management software company posted an adjusted quarterly loss of 11 cents per share, smaller than the 35-cent loss that analysts were anticipating. Revenue came in above estimates, and the company issued a better-than-expected outlook, but the shares fell 1.5% in the premarket.\nC3.ai, Inc. – The artificial intelligence software provider’s stock tumbled 7.7% in premarket trading after it reported a surprise quarterly loss. C3.ai lost an adjusted 37 cents per share for its latest quarter, compared with analyst forecasts of a 28 cents per share profit, and it also issued a weaker-than-expected current-quarter revenue outlook.\nFive Below – The discount retailer saw its stock slide 8.6% in the premarket, despite a 4-cent beat with quarterly earnings of $1.15 per share. Five Below’s revenue was shy of Street forecasts, and it is not giving sales or earnings guidance for the full year due to uncertainties surrounding Covid-19.\nCiena – The networking equipment maker earned an adjusted 92 cents per share for its latest quarter, beating estimates by 13 cents, while revenue beat estimates as well amid what the company calls “robust demand.” Separately, Ciena announced the acquisition ofAT&T’s (T) Vyatta virtual routing and switching technology unit. Ciena jumped 6.3% in premarket trading.","news_type":1,"symbols_score_info":{".SPX":0.9,".DJI":0.9,".IXIC":0.9}},"isVote":1,"tweetType":1,"viewCount":424,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9075851591,"gmtCreate":1658188040414,"gmtModify":1676536117956,"author":{"id":"3581901536452783","authorId":"3581901536452783","name":"Imeeng","avatar":"https://static.tigerbbs.com/e0aed7968b9134b940bf67762a13c6ea","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581901536452783","idStr":"3581901536452783"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NVAX\">$Novavax(NVAX)$</a>🫠🫠🫠","listText":"<a href=\"https://ttm.financial/S/NVAX\">$Novavax(NVAX)$</a>🫠🫠🫠","text":"$Novavax(NVAX)$🫠🫠🫠","images":[{"img":"https://community-static.tradeup.com/news/f35e815c93ee2a288ea87a74cd8fb69d","width":"1284","height":"2538"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9075851591","isVote":1,"tweetType":1,"viewCount":1030,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9009831115,"gmtCreate":1640600012165,"gmtModify":1676533528271,"author":{"id":"3581901536452783","authorId":"3581901536452783","name":"Imeeng","avatar":"https://static.tigerbbs.com/e0aed7968b9134b940bf67762a13c6ea","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581901536452783","idStr":"3581901536452783"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NVAX\">$Novavax(NVAX)$</a>pls like","listText":"<a href=\"https://ttm.financial/S/NVAX\">$Novavax(NVAX)$</a>pls like","text":"$Novavax(NVAX)$pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9009831115","isVote":1,"tweetType":1,"viewCount":1271,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":835436102,"gmtCreate":1629730689806,"gmtModify":1676530115561,"author":{"id":"3581901536452783","authorId":"3581901536452783","name":"Imeeng","avatar":"https://static.tigerbbs.com/e0aed7968b9134b940bf67762a13c6ea","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581901536452783","idStr":"3581901536452783"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BEKE\">$KE Holdings Inc.(BEKE)$</a>Vomit blood&nbsp;","listText":"<a href=\"https://laohu8.com/S/BEKE\">$KE Holdings Inc.(BEKE)$</a>Vomit blood&nbsp;","text":"$KE Holdings Inc.(BEKE)$Vomit blood","images":[{"img":"https://static.tigerbbs.com/ada0c7c723c4a9ab800e4fc9a0187fb3","width":"1284","height":"2457"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/835436102","isVote":1,"tweetType":1,"viewCount":735,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3564541694439920","authorId":"3564541694439920","name":"貔貅貅","avatar":"https://static.tigerbbs.com/8d6aec8b7f8256e9f0c966b8274ea7fe","crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3564541694439920","idStr":"3564541694439920"},"content":"It's selling early. I feel","text":"It's selling early. I feel","html":"It's selling early. I feel"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9999447012,"gmtCreate":1660576694938,"gmtModify":1676535717559,"author":{"id":"3581901536452783","authorId":"3581901536452783","name":"Imeeng","avatar":"https://static.tigerbbs.com/e0aed7968b9134b940bf67762a13c6ea","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581901536452783","idStr":"3581901536452783"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NVAX\">$Novavax(NVAX)$</a>Die Liao","listText":"<a href=\"https://ttm.financial/S/NVAX\">$Novavax(NVAX)$</a>Die Liao","text":"$Novavax(NVAX)$Die Liao","images":[{"img":"https://community-static.tradeup.com/news/db54022310cc98f9f33e5365a8839369","width":"1284","height":"2538"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9999447012","isVote":1,"tweetType":1,"viewCount":3451,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":885891525,"gmtCreate":1631773142967,"gmtModify":1676530631893,"author":{"id":"3581901536452783","authorId":"3581901536452783","name":"Imeeng","avatar":"https://static.tigerbbs.com/e0aed7968b9134b940bf67762a13c6ea","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581901536452783","idStr":"3581901536452783"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/885891525","repostId":"1189685868","repostType":4,"repost":{"id":"1189685868","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1631714905,"share":"https://ttm.financial/m/news/1189685868?lang=en_US&edition=fundamental","pubTime":"2021-09-15 22:08","market":"us","language":"en","title":"BioNTech SE stock jumped 4% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1189685868","media":"Tiger Newspress","summary":"BioNTech SE stock jumped 4% in morning trading as Pfizer said booster shots of vaccine restore wanin","content":"<p>BioNTech SE stock jumped&nbsp;4% in morning trading&nbsp;as&nbsp;Pfizer said booster shots of vaccine restore waning Immunity.Pfizer shares&nbsp;rose&nbsp;0.7%.</p>\n<p><img src=\"https://static.tigerbbs.com/fb4c307ca1b61c145bfb12a955ecf588\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>\n<p>Pfizer Inc.&nbsp;said that data from the U.S. and Israel suggest that the efficacy of its Covid-19 vaccine wanes over time, and that a booster dose was safe and effective at warding off the virus and new variants.</p>\n<p>The company detailed the data in a&nbsp;presentation&nbsp;it will deliver to a meeting of outside advisers to the Food and Drug Administration on Friday. The panel is expected to make recommendations for whether more Americans should receive booster shots.</p>\n<p>“Real-world data from Israel and the United States suggest that rates of breakthrough infections are rising faster in individuals who were vaccinated earlier,” Pfizer said in its presentation, which was posted on the FDA website. The drug giant is partnering with Germany’s&nbsp;BioNTech SE&nbsp;to make the shots.</p>\n<p>The decrease in effectiveness is “primarily due to waning of vaccine immune responses over time,” rather than the delta variant, Pfizer researchers said in the presentation.</p>\n<p><b>Unpublished Data</b></p>\n<p>According to a meeting&nbsp;agenda&nbsp;the FDA posted on its website, in addition to the Pfizer presentation, the Friday panel will include presentations from the Centers for Disease Control and Prevention, FDA staff and researchers from Israel and the U.K.</p>\n<p>The Israel officials will present data from that country on booster protection against infections and severe disease, according to the agenda, and a professor of medical statistics from the University of Bristol will present data on real-world vaccine effectiveness.</p>\n<p>While its vaccine continues to provide strong protection against hospitalizations and severe disease in the U.S., Pfizer said, data from Israel and elsewhere suggests that reduction in efficacy against infection may be followed by reduced effectiveness against severe disease, especially among vulnerable elderly people.</p>\n<p>Early unpublished data from an Israeli health maintenance organization suggest that a third booster dose is highly effective in areas where the delta variant is dominant, according to the Pfizer document. Giving a third dose to people more than 60 years old was associated with 86% effectiveness against testing positive for Covid starting at least a week after the booster, Pfizer said.</p>\n<p>Pfizer also detailed immune response results from a final-stage trial of booster shots in over 300 people, showing that a third dose bolstered blood antibody levels. One month after the third dose, levels of the protective antibodies were more than triple what they had been a month after the second shot.</p>\n<p>No new unexpected side effects were identified from safety data associated with boosters in the final-stage study, according to the Pfizer report. Consideration of a booster dose six months after a second dose of its shot is warranted, based on similarities between the outbreaks in Israel and the U.S., Pfizer said.</p>\n<p><b>Signs of Friction</b></p>\n<p>Marion Gruber, one of two top vaccine officials who FDA recently said will step down later this year, is also scheduled to speak. Gruber was co-author of an article in The Lancet earlier this week arguing that booster shots weren’t yet necessary for most people. The departures of the two longtime agency staff are a potential sign of friction over the Biden booster plan.</p>\n<p>The FDA hasn’t yet posted its staff report on the booster data. The agency’s documents are typically released 48 hours before the start of a panel meeting.</p>\n<p>The FDA is working as quickly as possible to post the items throughout the day as they are finalized and available, spokesperson Alison Hunt said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech SE stock jumped 4% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech SE stock jumped 4% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-09-15 22:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BioNTech SE stock jumped&nbsp;4% in morning trading&nbsp;as&nbsp;Pfizer said booster shots of vaccine restore waning Immunity.Pfizer shares&nbsp;rose&nbsp;0.7%.</p>\n<p><img src=\"https://static.tigerbbs.com/fb4c307ca1b61c145bfb12a955ecf588\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>\n<p>Pfizer Inc.&nbsp;said that data from the U.S. and Israel suggest that the efficacy of its Covid-19 vaccine wanes over time, and that a booster dose was safe and effective at warding off the virus and new variants.</p>\n<p>The company detailed the data in a&nbsp;presentation&nbsp;it will deliver to a meeting of outside advisers to the Food and Drug Administration on Friday. The panel is expected to make recommendations for whether more Americans should receive booster shots.</p>\n<p>“Real-world data from Israel and the United States suggest that rates of breakthrough infections are rising faster in individuals who were vaccinated earlier,” Pfizer said in its presentation, which was posted on the FDA website. The drug giant is partnering with Germany’s&nbsp;BioNTech SE&nbsp;to make the shots.</p>\n<p>The decrease in effectiveness is “primarily due to waning of vaccine immune responses over time,” rather than the delta variant, Pfizer researchers said in the presentation.</p>\n<p><b>Unpublished Data</b></p>\n<p>According to a meeting&nbsp;agenda&nbsp;the FDA posted on its website, in addition to the Pfizer presentation, the Friday panel will include presentations from the Centers for Disease Control and Prevention, FDA staff and researchers from Israel and the U.K.</p>\n<p>The Israel officials will present data from that country on booster protection against infections and severe disease, according to the agenda, and a professor of medical statistics from the University of Bristol will present data on real-world vaccine effectiveness.</p>\n<p>While its vaccine continues to provide strong protection against hospitalizations and severe disease in the U.S., Pfizer said, data from Israel and elsewhere suggests that reduction in efficacy against infection may be followed by reduced effectiveness against severe disease, especially among vulnerable elderly people.</p>\n<p>Early unpublished data from an Israeli health maintenance organization suggest that a third booster dose is highly effective in areas where the delta variant is dominant, according to the Pfizer document. Giving a third dose to people more than 60 years old was associated with 86% effectiveness against testing positive for Covid starting at least a week after the booster, Pfizer said.</p>\n<p>Pfizer also detailed immune response results from a final-stage trial of booster shots in over 300 people, showing that a third dose bolstered blood antibody levels. One month after the third dose, levels of the protective antibodies were more than triple what they had been a month after the second shot.</p>\n<p>No new unexpected side effects were identified from safety data associated with boosters in the final-stage study, according to the Pfizer report. Consideration of a booster dose six months after a second dose of its shot is warranted, based on similarities between the outbreaks in Israel and the U.S., Pfizer said.</p>\n<p><b>Signs of Friction</b></p>\n<p>Marion Gruber, one of two top vaccine officials who FDA recently said will step down later this year, is also scheduled to speak. Gruber was co-author of an article in The Lancet earlier this week arguing that booster shots weren’t yet necessary for most people. The departures of the two longtime agency staff are a potential sign of friction over the Biden booster plan.</p>\n<p>The FDA hasn’t yet posted its staff report on the booster data. The agency’s documents are typically released 48 hours before the start of a panel meeting.</p>\n<p>The FDA is working as quickly as possible to post the items throughout the day as they are finalized and available, spokesperson Alison Hunt said.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1189685868","content_text":"BioNTech SE stock jumped 4% in morning trading as Pfizer said booster shots of vaccine restore waning Immunity.Pfizer shares rose 0.7%.\n\nPfizer Inc. said that data from the U.S. and Israel suggest that the efficacy of its Covid-19 vaccine wanes over time, and that a booster dose was safe and effective at warding off the virus and new variants.\nThe company detailed the data in a presentation it will deliver to a meeting of outside advisers to the Food and Drug Administration on Friday. The panel is expected to make recommendations for whether more Americans should receive booster shots.\n“Real-world data from Israel and the United States suggest that rates of breakthrough infections are rising faster in individuals who were vaccinated earlier,” Pfizer said in its presentation, which was posted on the FDA website. The drug giant is partnering with Germany’s BioNTech SE to make the shots.\nThe decrease in effectiveness is “primarily due to waning of vaccine immune responses over time,” rather than the delta variant, Pfizer researchers said in the presentation.\nUnpublished Data\nAccording to a meeting agenda the FDA posted on its website, in addition to the Pfizer presentation, the Friday panel will include presentations from the Centers for Disease Control and Prevention, FDA staff and researchers from Israel and the U.K.\nThe Israel officials will present data from that country on booster protection against infections and severe disease, according to the agenda, and a professor of medical statistics from the University of Bristol will present data on real-world vaccine effectiveness.\nWhile its vaccine continues to provide strong protection against hospitalizations and severe disease in the U.S., Pfizer said, data from Israel and elsewhere suggests that reduction in efficacy against infection may be followed by reduced effectiveness against severe disease, especially among vulnerable elderly people.\nEarly unpublished data from an Israeli health maintenance organization suggest that a third booster dose is highly effective in areas where the delta variant is dominant, according to the Pfizer document. Giving a third dose to people more than 60 years old was associated with 86% effectiveness against testing positive for Covid starting at least a week after the booster, Pfizer said.\nPfizer also detailed immune response results from a final-stage trial of booster shots in over 300 people, showing that a third dose bolstered blood antibody levels. One month after the third dose, levels of the protective antibodies were more than triple what they had been a month after the second shot.\nNo new unexpected side effects were identified from safety data associated with boosters in the final-stage study, according to the Pfizer report. Consideration of a booster dose six months after a second dose of its shot is warranted, based on similarities between the outbreaks in Israel and the U.S., Pfizer said.\nSigns of Friction\nMarion Gruber, one of two top vaccine officials who FDA recently said will step down later this year, is also scheduled to speak. Gruber was co-author of an article in The Lancet earlier this week arguing that booster shots weren’t yet necessary for most people. The departures of the two longtime agency staff are a potential sign of friction over the Biden booster plan.\nThe FDA hasn’t yet posted its staff report on the booster data. The agency’s documents are typically released 48 hours before the start of a panel meeting.\nThe FDA is working as quickly as possible to post the items throughout the day as they are finalized and available, spokesperson Alison Hunt said.","news_type":1,"symbols_score_info":{"BNTX":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":917,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":863946052,"gmtCreate":1632355414276,"gmtModify":1676530759845,"author":{"id":"3581901536452783","authorId":"3581901536452783","name":"Imeeng","avatar":"https://static.tigerbbs.com/e0aed7968b9134b940bf67762a13c6ea","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581901536452783","idStr":"3581901536452783"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>won’t cut losses yet","listText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>won’t cut losses yet","text":"$Alibaba(BABA)$won’t cut losses yet","images":[{"img":"https://static.tigerbbs.com/b366aafad45dcba92bd4f6ca7dcf113a","width":"1284","height":"2223"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/863946052","isVote":1,"tweetType":1,"viewCount":1126,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":886859891,"gmtCreate":1631581508913,"gmtModify":1676530580715,"author":{"id":"3581901536452783","authorId":"3581901536452783","name":"Imeeng","avatar":"https://static.tigerbbs.com/e0aed7968b9134b940bf67762a13c6ea","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581901536452783","idStr":"3581901536452783"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>I’m planning to holdz","listText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>I’m planning to holdz","text":"$Alibaba(BABA)$I’m planning to holdz","images":[{"img":"https://static.tigerbbs.com/cc9e088e343a22abda0dd68446c01e34","width":"1284","height":"2223"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/886859891","isVote":1,"tweetType":1,"viewCount":823,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":836241485,"gmtCreate":1629503661547,"gmtModify":1676530058885,"author":{"id":"3581901536452783","authorId":"3581901536452783","name":"Imeeng","avatar":"https://static.tigerbbs.com/e0aed7968b9134b940bf67762a13c6ea","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581901536452783","idStr":"3581901536452783"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BEKE\">$KE Holdings Inc.(BEKE)$</a>Cut losses?","listText":"<a href=\"https://laohu8.com/S/BEKE\">$KE Holdings Inc.(BEKE)$</a>Cut losses?","text":"$KE Holdings Inc.(BEKE)$Cut losses?","images":[{"img":"https://static.tigerbbs.com/f40ee7db12c5c644a0f0f6fbc5595552","width":"1284","height":"2223"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/836241485","isVote":1,"tweetType":1,"viewCount":961,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"lives":[]}